WEBULL
News
IMMX
5.56
+14.88%
0.72
Immix Biopharma Unveils Breakthrough Approach for Relapsed AL Amyloidosis in New Presentation
Reuters · 3d ago
Immix Biopharma Unveils Breakthrough Strategy for Relapsed/Refractory AL Amyloidosis
Reuters · 3d ago
Weekly Report: what happened at IMMX last week (1124-1128)?
Weekly Report · 5d ago
Immix Biopharma Updates Accounting Firm Consents
TipRanks · 11/26 22:28
Weekly Report: what happened at IMMX last week (1117-1121)?
Weekly Report · 11/24 10:39
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 11/21 21:05
Weekly Report: what happened at IMMX last week (1110-1114)?
Weekly Report · 11/17 10:40
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 11/12 21:05
Immix Biopharma Appoints Michael Grabow as Chief Commercial Officer
Reuters · 11/12 13:45
IMMIX BIOPHARMA APPOINTS CHIEF COMMERCIAL OFFICER TO DRIVE NXC-201 LAUNCH
Reuters · 11/12 13:45
Immix Biopharma: Promising Trial Results and Strong Financial Position Justify Buy Rating
TipRanks · 11/10 11:36
Weekly Report: what happened at IMMX last week (1103-1107)?
Weekly Report · 11/10 10:37
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 11/07 21:05
Immix Biopharma: I Am Surprised To Reaffirm A 'Buy'
Seeking Alpha · 11/06 19:39
Immix Biopharma Unveils Breakthrough Approach for Relapsed AL Amyloidosis Treatment
Reuters · 11/03 20:42
Immix Biopharma To Present Phase 1/2 Interim Results From US NXC-201 NEXICART-2 Trial In Relapsed/Refractory AL Amyloidosis At ASH 2025
Benzinga · 11/03 13:48
Immix Biopharma to Present Phase 1/2 NXC-201 CAR-T Trial Results for AL Amyloidosis at ASH 2025
Reuters · 11/03 13:45
IMMIX BIOPHARMA’S NXC-201 NEXICART-2 CLINICAL TRIAL RESULTS SELECTED FOR ORAL PRESENTATION AT ASH 2025
Reuters · 11/03 13:45
Weekly Report: what happened at IMMX last week (1027-1031)?
Weekly Report · 11/03 10:37
Immix Biopharma’s NXC-201 CAR-T Study: A Potential Game-Changer for AL Amyloidosis
TipRanks · 10/27 18:55
More
Webull provides a variety of real-time IMMX stock news. You can receive the latest news about Immix Biopharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About IMMX
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and select immune-mediated diseases. The Company's lead cell therapy candidate CAR-T NXC-201 (NXC-201), which is being evaluated in its ongoing United States Phase Ib/II NEXICART-2 (NCT06097832) clinical trial. Its lead program, NXC-201 is a next generation CAR-T targeting B-cell maturation antigen. CAR-T cell therapy is a type of immunotherapy that uses the patient’s own immune cells, modified with its proprietary technology. Its N-GENIUS cell engineering platform with EXPAND technology has produced clinical-stage CAR-T NXC-201, targeting B cell maturation antigen, which is autologous CAR-T being developed to treat AL Amyloidosis.